See more : Scandi Standard AB (publ) (SCST.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xiangxue Pharmaceutical Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Reservoir Capital Corp. (RSERF) Income Statement Analysis – Financial Results
- E3 Lithium Limited (ETL.V) Income Statement Analysis – Financial Results
- Khaitan Chemicals and Fertilizers Limited (KHAICHEM.BO) Income Statement Analysis – Financial Results
- Capital Power Corp (CPRHF) Income Statement Analysis – Financial Results
- Synairgen plc (SYGGF) Income Statement Analysis – Financial Results
Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
About Xiangxue Pharmaceutical Co.,Ltd.
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.30B | 2.19B | 2.97B | 3.07B | 2.79B | 2.50B | 2.19B | 1.86B | 1.46B | 1.52B | 1.26B | 801.02M | 616.09M | 513.38M | 378.63M | 294.81M | 258.31M |
| Cost of Revenue | 1.51B | 1.64B | 2.19B | 2.08B | 1.91B | 1.59B | 1.54B | 1.27B | 839.08M | 888.86M | 742.58M | 417.53M | 327.17M | 271.37M | 184.40M | 141.75M | 136.59M |
| Gross Profit | 789.77M | 542.51M | 779.28M | 992.57M | 880.80M | 913.14M | 645.25M | 588.07M | 625.52M | 635.12M | 518.53M | 383.49M | 288.92M | 242.02M | 194.23M | 153.06M | 121.71M |
| Gross Profit Ratio | 34.35% | 24.81% | 26.23% | 32.31% | 31.61% | 36.46% | 29.50% | 31.58% | 42.71% | 41.68% | 41.12% | 47.88% | 46.90% | 47.14% | 51.30% | 51.92% | 47.12% |
| Research & Development | 102.81M | 94.79M | 90.60M | 66.99M | 61.27M | 38.67M | 40.05M | 33.29M | 45.60M | 50.76M | 31.60M | 25.66M | 19.71M | 15.51M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 64.57M | 88.10M | 105.96M | 91.36M | 63.58M | 66.49M | 53.12M | 44.62M | 31.03M | 32.80M | 28.52M | 22.44M | 16.51M | 13.44M | 39.52M | 29.20M | 26.00M |
| Selling & Marketing | 223.36M | 333.14M | 381.62M | 339.04M | 395.32M | 373.31M | 308.11M | 251.07M | 217.33M | 202.95M | 158.66M | 131.72M | 109.50M | 82.77M | 78.31M | 74.83M | 54.68M |
| SG&A | 287.93M | 421.24M | 487.58M | 430.39M | 458.90M | 439.79M | 361.23M | 295.69M | 248.37M | 235.74M | 187.19M | 154.16M | 126.01M | 96.20M | 117.83M | 104.03M | 80.67M |
| Other Expenses | 744.79M | 172.82M | 156.00M | 130.89M | 144.17M | -14.02M | 20.35M | 55.82M | 31.95M | 17.68M | 17.32M | 3.81M | 3.55M | 1.21M | 588.67K | 166.64M | -763.92K |
| Operating Expenses | 1.12B | 688.86M | 734.19M | 628.27M | 664.34M | 619.51M | 490.95M | 454.05M | 390.37M | 375.63M | 284.09M | 235.30M | 185.59M | 138.96M | 121.05M | 106.31M | 82.82M |
| Cost & Expenses | 2.63B | 2.33B | 2.93B | 2.71B | 2.57B | 2.21B | 2.03B | 1.73B | 1.23B | 1.26B | 1.03B | 652.83M | 512.76M | 410.32M | 305.46M | 248.05M | 219.42M |
| Interest Income | 1.20M | 3.91M | 8.25M | 5.10M | 4.17M | 6.26M | 3.76M | 8.95M | 19.75M | 20.48M | 18.48M | 17.67M | 13.64M | 1.25M | 97.93K | 99.84K | 202.49K |
| Interest Expense | 237.06M | 213.20M | 202.06M | 130.29M | 150.68M | 145.68M | 150.93M | 68.16M | 50.50M | 70.58M | 70.55M | 38.98M | 18.62M | 15.75M | 11.30M | 6.15M | 1.78M |
| Depreciation & Amortization | 237.30M | 247.08M | 164.89M | 149.84M | 121.81M | 105.52M | 112.47M | 105.52M | 83.40M | 69.24M | 42.15M | 33.78M | 24.51M | 18.41M | 14.11M | 15.20M | 15.19M |
| EBITDA | 151.22M | 89.36M | -238.12M | 319.63M | 412.43M | 370.33M | 405.33M | 289.99M | 357.68M | 365.01M | 308.05M | 202.25M | 143.87M | 122.21M | 86.19M | 62.22M | 51.98M |
| EBITDA Ratio | 6.58% | 4.09% | 6.22% | 15.08% | 14.00% | 17.51% | 19.41% | 16.04% | 25.58% | 24.42% | 24.73% | 25.38% | 23.51% | 24.12% | 23.19% | 77.19% | 20.79% |
| Operating Income | 53.79M | -152.93M | 34.99M | 327.97M | 275.21M | 126.03M | 105.55M | 59.21M | 185.56M | 206.94M | 177.33M | 125.69M | 97.19M | 86.84M | 60.11M | 35.32M | 35.78M |
| Operating Income Ratio | 2.34% | -6.99% | 1.18% | 10.68% | 9.88% | 5.03% | 4.83% | 3.18% | 12.67% | 13.58% | 14.06% | 15.69% | 15.78% | 16.92% | 15.87% | 11.98% | 13.85% |
| Total Other Income/Expenses | -442.74M | -337.42M | -657.33M | -145.71M | -158.13M | -140.99M | 20.35M | 54.65M | 31.94M | -33.16M | -35.63M | -17.67M | 3.55M | -13.29M | -10.69M | 5.36M | -763.92K |
| Income Before Tax | -388.95M | -514.72M | -635.78M | 166.14M | 117.08M | 112.00M | 125.90M | 114.60M | 217.50M | 224.60M | 194.66M | 129.50M | 100.75M | 88.05M | 60.70M | 40.68M | 35.01M |
| Income Before Tax Ratio | -16.92% | -23.53% | -21.40% | 5.41% | 4.20% | 4.47% | 5.76% | 6.15% | 14.85% | 14.74% | 15.44% | 16.17% | 16.35% | 17.15% | 16.03% | 13.80% | 13.56% |
| Income Tax Expense | 12.80M | -6.80M | 22.92M | 24.34M | -9.05M | 24.03M | 13.77M | 16.96M | 15.86M | 8.05M | 23.56M | 20.33M | 15.87M | 12.64M | 8.64M | 3.40M | 3.32M |
| Net Income | -388.96M | -507.92M | -658.70M | 141.80M | 126.13M | 56.44M | 65.94M | 66.02M | 177.30M | 196.80M | 158.24M | 107.17M | 83.50M | 74.20M | 50.92M | 35.95M | 30.78M |
| Net Income Ratio | -16.92% | -23.22% | -22.17% | 4.62% | 4.53% | 2.25% | 3.01% | 3.55% | 12.11% | 12.91% | 12.55% | 13.38% | 13.55% | 14.45% | 13.45% | 12.19% | 11.92% |
| EPS | -0.59 | -0.77 | -1.00 | 0.22 | 0.19 | 0.09 | 0.10 | 0.10 | 0.28 | 0.32 | 0.33 | 0.18 | 0.14 | 0.16 | 0.13 | 0.09 | 0.08 |
| EPS Diluted | -0.59 | -0.77 | -1.00 | 0.22 | 0.19 | 0.09 | 0.10 | 0.10 | 0.28 | 0.32 | 0.33 | 0.18 | 0.14 | 0.16 | 0.13 | 0.09 | 0.08 |
| Weighted Avg Shares Out | 659.26M | 658.72M | 658.72M | 655.30M | 652.71M | 627.10M | 659.39M | 660.24M | 633.21M | 614.99M | 477.45M | 600.49M | 608.22M | 454.01M | 396.38M | 399.96M | 396.51M |
| Weighted Avg Shares Out (Dil) | 659.26M | 658.72M | 658.72M | 655.30M | 652.71M | 627.10M | 659.39M | 660.24M | 633.21M | 614.99M | 477.45M | 600.49M | 608.22M | 454.01M | 396.38M | 399.96M | 396.51M |
Source: https://incomestatements.info
Category: Stock Reports